Skip to main content

First Report Managed Care

News

News
03/20/2026
Lisa Kuhns, PhD, MD
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help...
03/20/2026
First Report Managed Care
Behind the Bill
03/19/2026
Hannah Musick
A sweeping proposed Affordable Care Act (ACA) Marketplace rule for 2027 is drawing sharp pushback from states, setting up a high-stakes debate over coverage, affordability, and program integrity.
A sweeping proposed Affordable Care Act (ACA) Marketplace rule for 2027 is drawing sharp pushback from states, setting up a high-stakes debate over coverage, affordability, and program integrity.
A sweeping proposed Affordable...
03/19/2026
First Report Managed Care
News
03/18/2026
Hannah Musick
A systematic review of diffuse large B-cell lymphoma (DLBCL) registration trials found that while most primary outcomes are reported for older adults, key data on secondary endpoints, toxicity, and quality of life remain largely missing,...
A systematic review of diffuse large B-cell lymphoma (DLBCL) registration trials found that while most primary outcomes are reported for older adults, key data on secondary endpoints, toxicity, and quality of life remain largely missing,...
A systematic review of diffuse...
03/18/2026
First Report Managed Care
News
03/18/2026
Lisa Kuhns, PhD, MD
Decades of clinical trials are reshaping diabetic kidney disease care, with combination therapies now delivering unprecedented gains in renal and cardiovascular outcomes.
Decades of clinical trials are reshaping diabetic kidney disease care, with combination therapies now delivering unprecedented gains in renal and cardiovascular outcomes.
Decades of clinical trials are...
03/18/2026
First Report Managed Care
News
03/17/2026
Grace Taylor, MS, MA
Fixed-duration epcoritamab combined with rituximab plus lenalidomide (R2) delivers high complete response rates and durable remissions in relapsed or refractory (R/R) follicular lymphoma, according to a study published in Blood.
Fixed-duration epcoritamab combined with rituximab plus lenalidomide (R2) delivers high complete response rates and durable remissions in relapsed or refractory (R/R) follicular lymphoma, according to a study published in Blood.
Fixed-duration epcoritamab...
03/17/2026
First Report Managed Care
News
03/16/2026
Lisa Kuhns, PhD, MD
Bispecific antibodies are emerging as an effective, off-the-shelf option for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with promising response rates and growing evidence that they can be delivered safely in community...
Bispecific antibodies are emerging as an effective, off-the-shelf option for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with promising response rates and growing evidence that they can be delivered safely in community...
Bispecific antibodies are...
03/16/2026
First Report Managed Care
News
03/13/2026
Lisa Kuhns, PhD, MD
A real-world study suggests semaglutide not only drives meaningful weight loss but may also improve muscle strength and reduce sarcopenic obesity in patients with severe obesity.
A real-world study suggests semaglutide not only drives meaningful weight loss but may also improve muscle strength and reduce sarcopenic obesity in patients with severe obesity.
A real-world study suggests...
03/13/2026
First Report Managed Care
Behind the Bill
03/13/2026
Grace Taylor, MS, MA
A bipartisan Senate bill advancing toward floor consideration would mandate new cybersecurity standards under the Health Insurance Portability and Accountability Act, strengthen federal oversight, and expand breach transparency.
A bipartisan Senate bill advancing toward floor consideration would mandate new cybersecurity standards under the Health Insurance Portability and Accountability Act, strengthen federal oversight, and expand breach transparency.
A bipartisan Senate bill...
03/13/2026
First Report Managed Care
News
03/12/2026
Lisa Kuhns, PhD, MD
A single bispecific antibody used across multiple lymphoma indications could save oncology practices hundreds of thousands of dollars and thousands of staff hours annually, according to a new mixed-methods analysis published in Future...
A single bispecific antibody used across multiple lymphoma indications could save oncology practices hundreds of thousands of dollars and thousands of staff hours annually, according to a new mixed-methods analysis published in Future...
A single bispecific antibody...
03/12/2026
First Report Managed Care
News
03/11/2026
Hannah Musick
In an indirect comparison of third-line or later follicular lymphoma, epcoritamab demonstrated significantly higher response rates vs chemoimmunotherapy and favorable safety compared with other bispecific antibodies.
In an indirect comparison of third-line or later follicular lymphoma, epcoritamab demonstrated significantly higher response rates vs chemoimmunotherapy and favorable safety compared with other bispecific antibodies.
In an indirect comparison of...
03/11/2026
First Report Managed Care

KOL Insights

Real-World Data, Artificial Intelligence, Health Care
Commentary
02/11/2026
Sujay Jadhav
Health care generates massive amounts of real-world data (RWD), and that volume is only continuing to expand. By 2030, the global big data analytics market is expected to reach nearly $350 billion, with health care driving much of that...
Health care generates massive amounts of real-world data (RWD), and that volume is only continuing to expand. By 2030, the global big data analytics market is expected to reach nearly $350 billion, with health care driving much of that...
Health care generates massive...
02/11/2026
First Report Managed Care
NSCLC, Oncology Coverage, Oncology Access
Videos
02/02/2026
Narjust Florez, MD
In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...
In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...
In this interview, Narjust...
02/02/2026
First Report Managed Care
Non-Small Cell Lung Cancer
Videos
01/27/2026
Corrine Stahura, PharmD, BCOP
Corrine Stahura, PharmD, BCOP, discusses how extended dosing intervals and subcutaneous formulations in non–small cell lung cancer are improving patient convenience, reducing infusion center burden, and enhancing operational efficiency while...
Corrine Stahura, PharmD, BCOP, discusses how extended dosing intervals and subcutaneous formulations in non–small cell lung cancer are improving patient convenience, reducing infusion center burden, and enhancing operational efficiency while...
Corrine Stahura, PharmD, BCOP,...
01/27/2026
First Report Managed Care
Non-Small Cell Lung Cancer
Videos
01/27/2026
Rajat Thawani, MD
Dr Rajat Thawani discusses how biomarker-driven strategies, emerging immunotherapies, and novel delivery approaches are rapidly redefining first-line non-small cell lung cancer (NSCLC) treatment—shifting care beyond traditional chemotherapy...
Dr Rajat Thawani discusses how biomarker-driven strategies, emerging immunotherapies, and novel delivery approaches are rapidly redefining first-line non-small cell lung cancer (NSCLC) treatment—shifting care beyond traditional chemotherapy...
Dr Rajat Thawani discusses how...
01/27/2026
First Report Managed Care
Non-Small Cell Lung Cancer
Videos
01/27/2026
Estelamari Rodriguez, MD, MPH
As new subcutaneous and targeted therapies enter the NSCLC landscape, the true cost of care extends far beyond drug price alone. In this interview, Estelamari Rodriguez, MD, MPH, a thoracic oncologist at Sylvester Comprehensive Cancer Center,...
As new subcutaneous and targeted therapies enter the NSCLC landscape, the true cost of care extends far beyond drug price alone. In this interview, Estelamari Rodriguez, MD, MPH, a thoracic oncologist at Sylvester Comprehensive Cancer Center,...
As new subcutaneous and targeted...
01/27/2026
First Report Managed Care
Yuri Fesko, MD, PAMA, Health Care Policy, Medicare
Interview
01/22/2026
Yuri Fesko, MD
In this interview, senior vice president and chief medical officer at Quest Diagnostics, Yuri Fesko, MD, discusses how Medicare laboratory reimbursement under PAMA threatens access to precision cancer diagnostics—particularly for rural and...
In this interview, senior vice president and chief medical officer at Quest Diagnostics, Yuri Fesko, MD, discusses how Medicare laboratory reimbursement under PAMA threatens access to precision cancer diagnostics—particularly for rural and...
In this interview, senior vice...
01/22/2026
First Report Managed Care
Long-Term Care, Post-Acute Care, Lobbying, Politics
Commentary
01/20/2026
Bill Charnetski
Local long-term and post-acute care leaders can’t afford to sit out politics—by embracing grassroots advocacy, sharing their expertise, and building relationships with lawmakers, they can directly shape the policies that affect their...
Local long-term and post-acute care leaders can’t afford to sit out politics—by embracing grassroots advocacy, sharing their expertise, and building relationships with lawmakers, they can directly shape the policies that affect their...
Local long-term and post-acute...
01/20/2026
Annals of Long-Term Care
Rural Hospitals, Behavioral Health, Coverage Gaps
Interview
01/15/2026
Shannon Werb
Shannon Werb, CEO of Array Behavioral Care, explains how uncertainty around Affordable Care Act (ACA) subsidies and Medicaid eligibility threatens to disrupt behavioral health care first—fueling treatment gaps, increased emergency department...
Shannon Werb, CEO of Array Behavioral Care, explains how uncertainty around Affordable Care Act (ACA) subsidies and Medicaid eligibility threatens to disrupt behavioral health care first—fueling treatment gaps, increased emergency department...
Shannon Werb, CEO of Array...
01/15/2026
First Report Managed Care
Rutzler Headshot
Commentary
12/08/2025
Erin Rutzler
Health plans must urgently shift from reactive, manual fraud efforts to proactive, technology-driven prepay strategies—supported by unified teams and expert talent—to combat increasingly fast, sophisticated fraud, waste, and abuse schemes and...
Health plans must urgently shift from reactive, manual fraud efforts to proactive, technology-driven prepay strategies—supported by unified teams and expert talent—to combat increasingly fast, sophisticated fraud, waste, and abuse schemes and...
Health plans must urgently shift...
12/08/2025
First Report Managed Care
Regulatory Insights
12/05/2025
Adam Colborn, JD
As health policy debates resurface in Washington, unresolved battles over ACA subsidies, health savings accounts, and PBM reform are shaping a high-stakes landscape for payers heading into the new year.
As health policy debates resurface in Washington, unresolved battles over ACA subsidies, health savings accounts, and PBM reform are shaping a high-stakes landscape for payers heading into the new year.
As health policy debates...
12/05/2025
First Report Managed Care

Issue Features

Sponsored
10/16/2025
JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain in adults—the first and only oral pain signal inhibitor highly selective for NaV1.81
JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain in adults—the first and only oral pain signal inhibitor highly selective for NaV1.81
JOURNAVX is an oral nonopioid...
10/16/2025
First Report Managed Care
Infographic
08/06/2025
The infographic summarizes the FIBRONEER-IPF Phase 3 trial results, demonstrating nerandomilast significantly reduced the decline in forced vital capacity (FVC) over 52 weeks compared to placebo. Nerandomilast exhibited a favorable safety...
The infographic summarizes the FIBRONEER-IPF Phase 3 trial results, demonstrating nerandomilast significantly reduced the decline in forced vital capacity (FVC) over 52 weeks compared to placebo. Nerandomilast exhibited a favorable safety...
The infographic summarizes the...
08/06/2025
First Report Managed Care
Feature Story
05/12/2025
Lynn Carroll; Rahul Sharma
Health care organizations will be under increasing financial pressure in 2025 and beyond as they struggle to reduce costs while improving care quality—particularly as actions at the federal level threaten to severely disrupt the industry. Not...
Health care organizations will be under increasing financial pressure in 2025 and beyond as they struggle to reduce costs while improving care quality—particularly as actions at the federal level threaten to severely disrupt the industry. Not...
Health care organizations will...
05/12/2025
First Report Managed Care
Feature Story
05/12/2025
David J. Sand, MD, MBA; Lynn Carroll
Value-based care (VBC) is the future of health care. It is the best approach to improving patient outcomes, reducing costs and addressing overall population health through a focus on prevention, care coordination and overall wellness.
Value-based care (VBC) is the future of health care. It is the best approach to improving patient outcomes, reducing costs and addressing overall population health through a focus on prevention, care coordination and overall wellness.
Value-based care (VBC) is the...
05/12/2025
First Report Managed Care
Sponsored
03/27/2025
On behalf of Teva Pharmaceuticals, we are pleased to present the second edition of The Teva Biosimilars Trend Report. This report examines the latest issues, challenges, and developments in the rapidly evolving biosimilars market from the...
On behalf of Teva Pharmaceuticals, we are pleased to present the second edition of The Teva Biosimilars Trend Report. This report examines the latest issues, challenges, and developments in the rapidly evolving biosimilars market from the...
On behalf of Teva...
03/27/2025
First Report Managed Care

Interactive Features

Quiz
11/25/2025
True or False: The transformation of traditional health care call centers into “smart access hubs” relies entirely on artificial intelligence (AI) to manage all patient interactions and scheduling.
True or False: The transformation of traditional health care call centers into “smart access hubs” relies entirely on artificial intelligence (AI) to manage all patient interactions and scheduling.
True or False: The...
11/25/2025
First Report Managed Care
Quiz
10/29/2025
Hannah Musick
True or False: According to the GAO report, physician consolidation—particularly into hospital systems—has been linked to higher Medicare and commercial spending, with limited evidence that it improves care quality.
True or False: According to the GAO report, physician consolidation—particularly into hospital systems—has been linked to higher Medicare and commercial spending, with limited evidence that it improves care quality.
True or False: According to the...
10/29/2025
First Report Managed Care
Quiz
10/14/2025
True or False: UnitedHealthcare’s new UHC Store is a digital marketplace that allows members to purchase health insurance plans directly from the company.
True or False: UnitedHealthcare’s new UHC Store is a digital marketplace that allows members to purchase health insurance plans directly from the company.
True or False:...
10/14/2025
First Report Managed Care